Merck to acquire Acceleron Pharma to strengthen cardiovascular …
WEBSep 30, 2021 — Founded in 2003, Acceleron works in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. The Cambridge, Massachusetts biotech is focused on the transforming growth factor (TGF)-beta superfamily of proteins that play a central role in the regulation of cell growth, differentiation and repair.
Researchers: New data adds to body of evidence for efficacy of …
WEBMar 1, 2022 — City of Hope, a US cancer research and treatment organization, and Osel, a California based company developing LBPs for diseases linked to the disruption of the human microbiome, said Phase 1 trial data showed the use of bacterial strain, Clostridium butyricum MIYAIRI 588 (CBM588), in combination with nivolumab/ipilimumab “significantly improved” progression-free survival in patients with ...
US: BioIVT acquires serum, plasma and reagent producer
WEBJun 29, 2021 — BioIVT, which is focused on research models and services for drug and diagnostic development, has acquired Valley Biomedical, a company servicing the biotechnology, R&D and clinical diagnostics markets.
GE Healthcare Life Sciences completes transition into Cytiva
WEBApr 1, 2020 — In the one of the largest deals seen in the contract development and manufacturing organization (CDMO) sector, Danaher Corporation decided to spend $21.4bn (€19.5bn) to acquire GE Healthcare Life Sciences .. Now, with the deal complete, GE Healthcare Life Sciences has emerged at the other side rebranded as Cytiva.
AstraZeneca invests $135M on expanding biologics facility in …
WEBAug 29, 2024 — AstraZeneca has announced plans to expand its existing manufacturing operations at the Sweden Biomanufacturing Center in Södertälje, a Swedish town located near Stockholm.
Charles River and Rznomics pair up on gene therapy development, …
WEBJan 23, 2023 — Charles River Laboratories International, Inc and Rznomics Inc, a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, have established a viral vector contract development and manufacturing organization (CDMO) partnership.
Process intensification in biopharma manufacturing can boost …
WEBAug 31, 2022 — Higher yielding processes, faster manufacturing and fewer consumables can all help drive significant reductions in environmental impact, highlight a group of authors including scientists from Genentech, GlaxoSmithKline and Merck & Co in a paper published in New Biotechnology. “The process intensification approach aligns perfectly with the direction of the biopharmaceutical industry striving ...
Shoreline Biosciences and BeiGene collaborate on genetically …
WEBJun 10, 2021 — The partnership will focus on a portfolio of NK-based cell therapeutics, using San Diego, California-headquartered Shoreline’s iPSC-derived NK cell tech. Shoreline will receive an upfront cash payment of $45m from BeiGene with the potential for additional development, regulatory and commercial milestone payments.
Memo Therapeutics AG to clinically develop SARS-CoV-2 antibody
WEBDec 13, 2021 — “The Swiss Government’s support in advancing clinical development of our SARS-CoV-2 antibody is an important milestone as we rapidly build upon our excellent preclinical data,” said Karsten Fischer, CEO of Zurich-headquartered Memo Therapeutics AG. “We have been able to confirm outstanding activity in a relevant in vivo model supporting the significant potential of COVAB 36 in tackling ...
Amgen v Sanofi ruling: It is time to kiss goodbye to broad, …
WEBMar 25, 2021 — Resolution Therapeutics scores £63.5 million Series B; Chiesi Group launches biotechnology center in Italy, backed by a €400m investment; Self-amplifying mRNA COVID-19 vaccine shows superiority over conventional mRNA vaccine